BioMedPartners
VC Fund
Basel, Switzerland
BioMedPartners is a VC fund in Basel focused on Biotechnology and Health Care. BioMedPartners is one of the leading European venture capital firms providing private equity and mezzanine financing to early- and mid-stage healthcare and human life science companies. They target the entire industry with special focus on pharmaceuticals, biotechnology, diagnostics and medical technology.
- Total investments:
- 88
- Last investment:
- Lead investor:
- 34%
- Fund size:
- $113M
- Last fund:
Last updated:
For AI agents: llms.txt
Industries BioMedPartners invests in
Stages BioMedPartners invests in
Countries BioMedPartners invests in
Round sizes
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Round size
- Series A
- $5.3M–$31M
- Series B
- $4.9M–$75M
- Series C
- $5.8M–$47M
Investment Focus
Industry
- Biotechnology 41 (47%)
- Health Care 31 (35%)
- Medical 16 (18%)
- Therapeutics 14 (16%)
- Pharmaceutical 11 (13%)
Stage
- Series A 26 (30%)
- Series B 22 (25%)
- Series C 13 (15%)
- Series D 3 (3%)
- Funding Round 3 (3%)
Country
- Switzerland 23 (26%)
- Germany 15 (17%)
- France 3 (3%)
- Belgium 2 (2%)
- United States 2 (2%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
Fiona Lauscher
Office Manager
|
Office Manager | Total investments: 0 | Find email | |
Karl Deres
Venture Partner
|
Venture Partner | Total investments: 0 | Find email | |
Markus Hosang
General Partner
|
General Partner | Total investments: 10 | Find email | |
Patrick Burgermeister
Partner
|
Partner | Total investments: 7 | Find email | |
Stefan Fäs
Chief Financial Officer & Partner
|
Chief Financial Officer & Partner | Total investments: 0 | Find email | |
| See all 7 team members → | ||||
Investments
| Company | Description | Round | Links |
|---|---|---|---|
iDEL Therapeutics
|
iDEL Therapeutics is advancing a new class of cancer medicines by delivering therapeutic payloads directly into the cytosol of tumor cells through a unique, pan-cancer uptake mechanism. | $10.4M / Seed / Mar 17, 2026 | |
T-CURX
|
T-CURX is a biotechnology company focused on the development of personalized cancer immunotherapies. Utilizing a proprietary platform, T-CURX aims to advance the field of T cell therapies to address the challenges faced in treating various cancers. The company's innovative approach involves the creation of a new generation of T cells designedto improve patient outcomes. As a spin-out from the University Clinics Würzburg, Germany, T-CURX leverages the expertise of its co-founders, including Prof. Michael Hudecek, to pioneer in the area of CAR-T cell-based medicines. With a commitment to transforming cancer treatment, T-CURX is at the forefront of developing targeted therapies that offer hope for a more effective and personalized approach to cancer care. | $20M / Series A / Dec 17, 2025 | |
ImmunOs Therapeutics
|
ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease. | $11M / Series C / Sep 17, 2024 | |
Tubulis
|
Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. | $139.3M / Series B / Mar 14, 2024 | |
TOLREMO therapeutics
|
TOLREMO therapeutics is a developer of small molecules intended to target novel drug resistance pathways in cancer therapy.The company's molecules specifically eradicate those cancer cells that cause drug resistance, enabling physicians to get personalized anti-drug resistance therapies to meaningfully prolong the lives of cancer patients. | $37.9M / Series A / Sep 20, 2023 | |
Tricares
|
TRiCares is a medical device company, devoted to developing a catheter-based valve replacement system for minimal invasive treatment of tricuspid valve regurgitation. | $46.9M / Series C / Sep 15, 2022 | |
|
ImmunOs Therapeutics
|
ImmunOs Therapeutics AG is a clinical-stage biotechnology company focused on discovering and developing next generation and novel human immunomodulatory proteins with a role in both innate and adaptive immunity.Their mission is to develop the next generation of novel therapeutics that will improve the lives of patients with serious disease. | $72.9M / Series B / Jun 07, 2022 | |
|
Tubulis
|
Tubulis is a biotechnology company that develops antibody-drug conjugates (ADCs) for targeted cancer therapy. The company combines proprietary technologies with disease-specific biological insights to create highly stable and effective protein-drug conjugates. Its platform enables the design of ADCs with improved delivery, reduced toxicity, andenhanced therapeutic potential across various cancer types, including solid and hematologic tumors. Tubulis is advancing a pipeline of experimental drug candidates, such as TUB-040 and TUB-030, which are currently being evaluated in clinical settings for cancers like ovarian and lung cancer. The company also collaborates with industry partners and leverages its proprietary conjugation technologies to expand the scope and effectiveness of targeted oncology treatments. | $63.2M / Series B / May 03, 2022 | |
Precirix
|
Developing radio-immunotherapeutic drugs for cancer patients. | $88.2M / Series B / Mar 16, 2022 | |
Scenic Biotech
|
Scenic Biotech is a developer of a genomics and immunotherapy technologies created to unlock genetic suppressors as a new class of drug targets.The company's immunotherapy technologies tackle diseases on the genetic level and focuses on disease suppressing genes., it uses genomics to develop innovative therapies for patients affected by severediseases. | $31M / Series A / Mar 09, 2022 | |
| See all 88 investments → | |||
Co-Investors
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar industry
Similar stage
Featured in Investor Lists
Recommended lists
FAQ
What does BioMedPartners invest in?
BioMedPartners invests primarily in Biotechnology, Health Care and Medical startups, most often at Series A and Series B stage. Most of the 88 investments tracked by Shizune back companies in Switzerland. The Investment Focus section breaks down every industry, stage and country in the portfolio.
What is BioMedPartners's check size?
BioMedPartners typically joins rounds of $5.3M–$31M at Series A, $4.9M–$75M at Series B and $5.8M–$47M at Series C. These ranges are 10th–90th percentile round sizes calculated from confirmed public funding rounds, so they are a realistic guide to the rounds BioMedPartners participates in.
How do I contact BioMedPartners?
Public channels for BioMedPartners include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at BioMedPartners?
The team at BioMedPartners includes Fiona Lauscher (Office Manager), Karl Deres (Venture Partner) and Markus Hosang (General Partner), among 7 team members tracked by Shizune. The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
